Clinical and immunomodulatory effects of celecoxib plus Interferon-Alpha in Metastatic Renal Cell Carcinoma patients with COX-2 tumor immunostaining

Journal of Clinical Immunology

Volumn 31, Issue 4, 2011, Pages 690-698

  Schwandt, Anita ^a   Garcia, Jorge A ^a   Elson, Paul ^b   Wyckhouse, Jeanie ^a   Finke, James H ^b   Ireland, Joanna ^b   Triozzi, Pierre ^a   Zhou, Ming ^b   Dreicer, Robert ^a   Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Celecoxib; Immunotherapy; Interferon ; Renal cell carcinoma; T regulatory cells

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CELECOXIB; CYCLOOXYGENASE 2; GAMMA INTERFERON; PROSTAGLANDIN E2; SORAFENIB; SUNITINIB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHRECTOMY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTAGLANDIN BLOOD LEVEL; PROTEIN EXPRESSION; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, RENAL CELL; CYCLOOXYGENASE 2; DENDRITIC CELLS; DINOPROSTONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRAZOLES; SULFONAMIDES; TH1 CELLS; TH1-TH2 BALANCE; TH2 CELLS; TREATMENT OUTCOME;

EID: 80054011717     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9530-x     Document Type: Article

References (23)

1. Onishi T et al. An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma. BJU Int. 1999;83(4):488-92. (Pubitemid 29151178)
2. Griffiths RW et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother. 2007;56(11):1743-53. (Pubitemid 47313079)
3. Wolf AM et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9(2):606-12. (Pubitemid 36182591)
4. Li JF et al. The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. BJU Int.2009;103(3):399-405.
5. Troy AJ et al. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res. 1998;4 (3):585-93. (Pubitemid 28193556)
6. Kiertscher SM et al. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol.2000;164(3):1269-76. (Pubitemid 30067239)
7. Gigante M et al. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. J Immunother. 2008;31(3):254-62. (Pubitemid 351441004)
8. Steitz J et al. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res. 2001;61 (24):8643-6. (Pubitemid 34013869)
9. Buszello H. Antiproliferative effects of four different cytokines on renal carcinoma cell lines. Anticancer Res. 1995;15(3):735-8.
10. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res. 2000;6(1):135-8. (Pubitemid 30064985)
11. Masferrer JL et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60(5):1306-11. (Pubitemid 30151999)
12. Waldmann TA. The interleukin-2 receptor. J Biol Chem. 1991;266 (5):2681-4. (Pubitemid 21909116)
13. Akasaki Yet al. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol.2004;173(7):4352-9. (Pubitemid 39280663)
14. Harizi H et al. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol. 2002;168(5):2255-63. (Pubitemid 34171825)
15. Sharma S et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res. 2003;9(3):961-8. (Pubitemid 36323698)
16. Sharma S et al. Tumor cyclooxygenase-2/prostaglandin E2- dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005;65 (12):5211-20. (Pubitemid 40827331)
17. Rini BI et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer. 2006;106(3):566-75. (Pubitemid 43157619)
18. Therasse P et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst.2000;92(3):205-16.
19. Motzer RJ et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289-96. (Pubitemid 34032623)
20. Miyata Y et al. Expression of cyclooxygenase-2 in renal cell carcinoma: Correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res. 2003;9(5):1741-9. (Pubitemid 36554599)
21. Kankuri-Tammilehto MK et al. Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer Res. 2010;30 (7):3023-30.
22. Negrier S et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: Results of a randomized controlled trial. Cancer. 2007;110(11):2468-77. (Pubitemid 350174932)
23. Tatsugami K, Eto M, Naito S. Influence of immunotherapy with interferon-alpha on regulatory T cells in renal cell carcinoma patients. J Interferon Cytokine Res. 2010;30(1):43-8.